Cardioselective beta-blockers for chronic obstructive pulmonary disease
about
Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary diseaseBeta-blocker use and COPD mortality: a systematic review and meta-analysisDefining and targeting health disparities in chronic obstructive pulmonary diseaseMedical Management of Glaucoma in the 21st Century from a Canadian PerspectiveIncreased risk of sudden cardiac arrest in obstructive pulmonary disease: a case-control studyEffect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare recordsEffect of β-blockade on lung function, exercise performance and dynamic hyperinflation in people with arterial vascular disease with and without COPD.Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary disease.Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD).Resting heart rate is a risk factor for mortality in chronic obstructive pulmonary disease, but not for exacerbations or pneumoniaQuality of care of hospitalized internal medicine patients bedspaced to non-internal medicine inpatient units.Epidemiology and clinical impact of major comorbidities in patients with COPD.Systematic review of methods used in meta-analyses where a primary outcome is an adverse or unintended eventImpact of chronic obstructive pulmonary disease on morbidity and mortality after myocardial infarctionUtilization of evidence-based treatment in elderly patients with chronic heart failure: using Korean Health Insurance claims database.Vulnerable COPD patients with comorbidities: the role of roflumilast.Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies.High blood pressure, antihypertensive medication and lung function in a general adult populationEffect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort studyImpact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary diseaseIncreased adverse events after percutaneous coronary intervention in patients with COPD: insights from the National Heart, Lung, and Blood Institute dynamic registry.Association between β-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension.The impact of COPD on management and outcomes of patients hospitalized with acute myocardial infarction: a 10-year retrospective observational study.β-blocker use and mortality in COPD patients after myocardial infarction: a Swedish nationwide observational study.Lung Disease and Hypertension.Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease.β-Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (βLOCK COPD): a randomised controlled study protocolCurrent perspectives on treatment of hypertensive patients with chronic obstructive pulmonary diseaseCoronary artery disease is under-diagnosed and under-treated in advanced lung disease.Cardiovascular injury and repair in chronic obstructive pulmonary disease.Cardiac disease in chronic obstructive pulmonary diseaseDo general practitioners follow treatment recommendations from guidelines in their decisions on heart failure management? A cross-sectional studyImpact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease.Beta-blockers and health-related quality of life in patients with peripheral arterial disease and COPD.β-Blockers are associated with a reduction in COPD exacerbations.Noncardiac comorbidities and acute heart failure patients.The safety of beta-blocker use in chronic obstructive pulmonary disease patients with respiratory failure in the intensive care unitAcute exacerbation of chronic obstructive pulmonary disease: cardiovascular links.Beta-blocker management of refractory hemoptysis in cystic fibrosis: a novel treatment approach.Beta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, nitrate-hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID(2) ): an evidence-based mnemonic for the treatment of systolic heart
P2860
Q27000043-1D84C326-AA55-4C89-8EA6-29A403D785ACQ27026866-7A0528E5-16E0-4A40-8DD0-355C5EC3603AQ28073617-90338FA9-0124-4A10-8105-F9C847879E3FQ28074316-DF7759DE-D602-47D6-BCBB-069A814323AAQ28533685-81293F3E-D907-4392-A3AA-42224A230782Q28660388-B59AB5EF-4858-41EE-9240-64B1AA21B832Q33552577-F402FC12-D2FD-4B7F-810B-5CE5B39105B3Q33565787-A37BE690-78DF-4ADA-8A32-B5FCDD3A455FQ33814586-3823D06C-AED7-41FC-AFAC-581C28EC373DQ34089856-4E02AED0-D536-43C3-BA14-448EE4B18D60Q34129104-C18B01EB-8A8C-4551-BC3B-903541B98D96Q34134841-53605F63-CBD5-4BBF-85BB-40185ACD05D7Q34254787-F6906C67-B572-4D07-A1F2-75127FB34A5CQ34304837-F434E84A-4312-4567-9B94-5BD82A0F6614Q34360297-1C380054-89DF-4A6F-BC3E-5979A8F8D775Q34566361-E3B4A342-CE60-480D-A8B0-6727EF3D3768Q34575920-F391D746-2C15-43E2-AA0E-9402578ABD65Q34961913-8EACA5BA-6DC9-43DB-8034-652BD29684A2Q34966373-B26B033B-5A33-4F2F-BBDC-A856040075BBQ35168749-787C6707-A50F-4C34-8CF4-32C94CEF085BQ35201848-977C0552-688D-45EB-9E97-F16E12A58488Q35680413-93DDB62E-CA4D-474F-B3B5-345B6928913CQ36009093-0E4FB819-6AA9-446B-B829-D2B9B44F805CQ36085731-CC3DBAD3-7A30-4E1E-A5BA-3213A83A723DQ36283226-E6157DAF-0BA1-4D43-9A8D-AEC8E51ACECEQ36566759-0E3BD686-2B22-4F43-ACF1-84C620033AD7Q37006972-45ADE099-244B-4990-809D-7CBCCB0C5D55Q37047304-2B386086-A4B2-4A2D-A612-56F615ED4025Q37066051-8FF48229-7A75-43BB-99C4-6F2A780DCB0EQ37098445-4F5F0B44-B0E4-4598-9198-6D8260E7743FQ37103712-D8F90DCE-3683-4386-B3DA-3280C5323A57Q37190371-4196D9EE-1F1C-4B2A-A351-F163656B7AEFQ37198408-3E4E1B33-E057-4D95-995C-ACE6435F8663Q37199663-2C38D801-6C46-4E2E-98FA-1EDAC06B06D4Q37499919-52A89B7E-51D0-4530-8C1A-C6B079CD0002Q37531314-B75F2417-D60E-40FF-84C4-0DFA21722710Q37579547-7E6A6820-3425-4D31-9252-9308E36805EAQ37644823-CB5DC547-54FA-4045-AC1E-D96FFF0E8E97Q38094066-1909C9ED-7C7E-4338-9A8A-27E851F43B47Q38537344-4F024C68-CC9C-448E-B07D-2EAA451E69A8
P2860
Cardioselective beta-blockers for chronic obstructive pulmonary disease
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Cardioselective beta-blockers for chronic obstructive pulmonary disease
@ast
Cardioselective beta-blockers for chronic obstructive pulmonary disease
@en
Cardioselective beta-blockers for chronic obstructive pulmonary disease
@en-gb
Cardioselective beta-blockers for chronic obstructive pulmonary disease
@nl
type
label
Cardioselective beta-blockers for chronic obstructive pulmonary disease
@ast
Cardioselective beta-blockers for chronic obstructive pulmonary disease
@en
Cardioselective beta-blockers for chronic obstructive pulmonary disease
@en-gb
Cardioselective beta-blockers for chronic obstructive pulmonary disease
@nl
prefLabel
Cardioselective beta-blockers for chronic obstructive pulmonary disease
@ast
Cardioselective beta-blockers for chronic obstructive pulmonary disease
@en
Cardioselective beta-blockers for chronic obstructive pulmonary disease
@en-gb
Cardioselective beta-blockers for chronic obstructive pulmonary disease
@nl
P2093
P2860
P3181
P1476
Cardioselective beta-blockers for chronic obstructive pulmonary disease
@en
P2093
Edwin E Salpeter
Shelley R Salpeter
Thomas M Ormiston
P2860
P3181
P356
10.1002/14651858.CD003566.PUB2
P577
2005-10-19T00:00:00Z